Product Description
Mechanisms of Action: LOXL2 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias|Cholangitis, Sclerosing|Pancreatic Cancer|Fatty Liver, Alcoholic|Liver Cirrhosis, Alcoholic|Non-alcoholic Steatohepatitis|Polycythemia Vera|Myelofibrosis|Hepatitis A|Thrombocythemia, Essential|Thrombocytosis|Liver Cirrhosis|Hepatitis, Alcoholic|Adenocarcinoma|Hepatitis C|Coinfection|Colorectal Cancer
Phase 1: Oncology Solid Tumor Unspecified|Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2012-002489-11 | P2 |
Terminated |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Liver Cirrhosis |
2019-01-26 |
|
| 2012-002488-88 | P2 |
Completed |
Liver Cirrhosis|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2016-12-29 |
|
| NASH | P2 |
Terminated |
Non-alcoholic Steatohepatitis|Liver Cirrhosis |
2016-09-26 |
|
| 2012-002473-61 | P2 |
Completed |
Cholangitis, Sclerosing |
2016-08-24 |